Related Experiment Video

Updated: Jan 30, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.8K

microRNAs in chronic kidney disease

Hui Zhao1, Shi-Xing Ma2, You-Quan Shang2

  • 1Faculty of Life Science & Medicine, Northwest University, No. 229 Taibai North Road, Xi'an, Shaanxi 710069, China.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|January 15, 2019
PubMed

Insights

MicroRNAs (miRNAs) play a key role in chronic kidney disease (CKD) progression. These molecules show potential as diagnostic biomarkers and therapeutic targets for managing CKD.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Chronic kidney disease (CKD) presents a significant global health challenge, marked by high morbidity, mortality, and socioeconomic impact.
  • MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and are implicated in various pathophysiological processes, including CKD.
  • Altered miRNA expression is a documented feature of CKD, prompting research into their specific roles.

Purpose of the Study:

  • To review current research on the involvement of miRNAs in the progression of chronic kidney disease.
  • To highlight the potential of miRNAs as diagnostic biomarkers for CKD.
  • To explore the therapeutic potential of targeting miRNAs in CKD treatment.

Main Methods:

  • Literature review of recent studies investigating miRNA involvement in CKD.
  • Analysis of research focusing on specific CKD states such as diabetic nephropathy, lupus nephritis, focal segmental glomerulosclerosis, and IgA nephropathy.
  • Synthesis of findings regarding miRNA expression changes and their functional roles in CKD pathogenesis.

Main Results:

  • Numerous studies demonstrate significant alterations in miRNA expression profiles in patients with CKD.
  • Specific miRNAs are linked to the progression of various CKD subtypes, including diabetic nephropathy and IgA nephropathy.
  • miRNAs are shown to influence key pathophysiological pathways relevant to kidney damage.

Conclusions:

  • MicroRNAs are critically involved in the progression of chronic kidney disease.
  • miRNAs represent promising candidates for developing novel diagnostic biomarkers for CKD.
  • Targeting miRNAs offers a potential therapeutic strategy for the management of chronic kidney disease.
Keywords:
Chronic kidney diseaseDiabetic nephropathyFocal segmental glomerulosclerosisIgA nephropathyLupus nephritismicroRNA

More Related Videos

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

2.2K
A Quantitative Detection Method for MicroRNAs in the Kidney of an Ischemic Kidney Injury Mouse Model07:01

A Quantitative Detection Method for MicroRNAs in the Kidney of an Ischemic Kidney Injury Mouse Model

Published on: September 11, 2020

1.9K

Related Concept Videos

Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
728
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
646
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
467
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
388
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.2K
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.5K